# Quan Capital

> Quan Capital is a VC fund in Shanghai backing Biotechnology and Health Care. See 41 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 41
- Last investment: May 2026
- Lead investor: 27%
- Fund size: $350M
- Last fund: Sep 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/quancapital
- Website: https://www.quancapital.com

Quan Capital is a VC fund in Shanghai focused on Biotechnology and Health Care. Quan Capital discover, incubate and grow next-generation life sciences companies. Their unique investment philosophy enables us to explore disruptive solutions to critical healthcare problems impacting the lives of millions. Their portfolio companies are pioneers in breakthrough therapies and cutting-edge technologies that will generate significantvalue to patients. In addition, they are investing in leading players that fulfill the rapid growing needs in a nascent innovation driven eco-system in China.

## Contacts

5 contacts available for Quan Capital. Shizune tracks 4 team members at Quan Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/quan-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 16 | 39% |
| Health Care | 13 | 32% |
| Pharmaceutical | 11 | 27% |
| Biopharma | 9 | 22% |
| Medical | 7 | 17% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 13 | 32% |
| Series A | 11 | 27% |
| Funding Round | 3 | 7% |
| Series C | 2 | 5% |
| Seed | 1 | 2% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 12 | 29% |
| China | 9 | 22% |
| Hong Kong | 1 | 2% |
| Switzerland | 1 | 2% |
| United Kingdom | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Marietta Wu | Managing Director | 9 | https://shizune.co/investors/profile/marietta-wu |
| Peter Wirth | Venture Partner | 0 | https://shizune.co/investors/profile/peter-wirth |
| Samantha DU | Founder & Managing Director | 0 | https://shizune.co/investors/profile/dr-samantha-du |
| Stella Xu | Managing Director | 7 | https://shizune.co/investors/profile/stella-xu |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Windward Bio | Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M | Series B | May 04, 2026 |  |
| Pinnacle Medicines | Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. | $89M | Series B | Mar 26, 2026 |  |
| Avenzo Therapeutics | Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $60M | Series B | Sep 04, 2025 |  |
| Windward Bio | Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $200M | Series A | Jan 10, 2025 |  |
| Avenzo Therapeutics | Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $50M | Series A | Nov 18, 2024 |  |
| Zenas BioPharma | Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA. | $200M | Series C | May 07, 2024 |  |
| Avenzo Therapeutics | Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $150M | Series A | Mar 26, 2024 |  |
| Crescendo Biologics | Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies. | $32M |  | Jul 24, 2023 |  |
| Adcentrx Therapeutics | Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies forimproving patient treatment options. | $51M | Series A | Apr 24, 2023 |  |
| Alebund Pharmaceuticals | Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $29.1M | Series C | Apr 12, 2023 |  |

10 of 41 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 9 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 9 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 8 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 7 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 6 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 6 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Life Science Investors in Switzerland](https://shizune.co/investors/life-science-investors-switzerland)

## FAQ

### What does Quan Capital invest in?

Quan Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 41 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Quan Capital?

Public channels for Quan Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Quan Capital?

The team at Quan Capital includes Marietta Wu (Managing Director), Peter Wirth (Venture Partner) and Samantha DU (Founder & Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co